Display options
Share it on

Circulation. 2013 Oct 08;128(15):1612-22. doi: 10.1161/CIRCULATIONAHA.113.002659. Epub 2013 Aug 22.

β1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapy.

Circulation

Alessandro Cannavo, Giuseppe Rengo, Daniela Liccardo, Gennaro Pagano, Carmela Zincarelli, Maria Carmen De Angelis, Roberto Puglia, Elisa Di Pietro, Joseph E Rabinowitz, Maria Vittoria Barone, Plinio Cirillo, Bruno Trimarco, Timothy M Palmer, Nicola Ferrara, Walter J Koch, Dario Leosco, Antonio Rapacciuolo

Affiliations

  1. Division of Geriatrics, Department of Translational Medical Sciences (A.C., G.R., D.L., G.P., N.F., D.L.), Department of Pediatrics and European Laboratory for the Investigation of Food-Induced Diseases (M.V.B.), and Division of Cardiology, Department of Advanced Biomedical Sciences (M.C.D.A., R.P., E.D.P., P.C., B.T., A.R.), Federico II University, Naples, Italy; Center of Translational Medicine, Temple University, Philadelphia, PA (A.C., J.E.R., W.J.K.); Division of Cardiology, Salvatore Maugeri Foundation, IRCCS, Scientific Institute of Telese Terme (BN), Italy (G.R., C.Z., N.F.); and the Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (T.M.P.).

PMID: 23969695 PMCID: PMC3952877 DOI: 10.1161/CIRCULATIONAHA.113.002659

Abstract

BACKGROUND: The sphingosine-1-phosphate receptor 1 (S1PR1) and β1-adrenergic receptor (β1AR) are G-protein-coupled receptors expressed in the heart. These 2 receptors have opposing actions on adenylyl cyclase because of differential G-protein coupling. Importantly, both of these receptors can be regulated by the actions of G-protein-coupled receptor kinase-2, which triggers desensitization and downregulation processes. Although classic signaling paradigms suggest that simultaneous activation of β1ARs and S1PR1s in a myocyte would simply result in opposing action on cAMP production, in this report we have uncovered a direct interaction between these 2 receptors, with regulatory involvement of G-protein-coupled receptor kinase-2.

METHODS AND RESULTS: In HEK (human embryonic kidney) 293 cells overexpressing both β1AR and S1PR1, we demonstrated that β1AR downregulation can occur after stimulation with sphingosine-1-phosphate (an S1PR1 agonist), whereas S1PR1 downregulation can be triggered by isoproterenol (a β-adrenergic receptor agonist) treatment. This cross talk between these 2 distinct G-protein-coupled receptors appears to have physiological significance, because they interact and show reciprocal regulation in mouse hearts undergoing chronic β-adrenergic receptor stimulation and in a rat model of postischemic heart failure.

CONCLUSIONS: We demonstrate that restoration of cardiac plasma membrane levels of S1PR1 produces beneficial effects that counterbalance the deleterious β1AR overstimulation in heart failure.

Keywords: genetic therapy; heart failure; hypertrophy; receptors, adrenergic, beta; signal transduction

References

  1. Circulation. 2003 Sep 30;108(13):1611-8 - PubMed
  2. Am J Cardiol. 1978 Feb;41(2):233-43 - PubMed
  3. N Engl J Med. 1982 Jul 22;307(4):205-11 - PubMed
  4. Eur J Heart Fail. 2009 Feb;11(2):140-6 - PubMed
  5. J Card Fail. 2002 Dec;8(6 Suppl):S409-14 - PubMed
  6. J Am Coll Cardiol. 2005 Sep 20;46(6):e1-82 - PubMed
  7. J Biol Chem. 2010 May 21;285(21):16378-86 - PubMed
  8. Eur J Pharmacol. 2006 Jul 1;540(1-3):131-8 - PubMed
  9. Cardiovasc Res. 2008 May 1;78(2):385-94 - PubMed
  10. Pharmacol Ther. 2001 Nov-Dec;92(2-3):71-87 - PubMed
  11. J Biol Chem. 2002 Feb 22;277(8):5767-77 - PubMed
  12. Glycobiology. 2010 Jan;20(4):473-84 - PubMed
  13. J Clin Invest. 2005 Aug;115(8):2108-18 - PubMed
  14. J Mol Cell Cardiol. 2011 Oct;51(4):534-41 - PubMed
  15. J Physiol. 2007 Feb 15;579(Pt 1):127-45 - PubMed
  16. J Biol Chem. 2003 Sep 12;278(37):35403-11 - PubMed
  17. Am J Physiol. 1981 May;240(5):H691-6 - PubMed
  18. Exp Mol Med. 2009 Apr 30;41(4):226-35 - PubMed
  19. Clin Transl Sci. 2010 Jun;3(3):81-9 - PubMed
  20. J Biol Chem. 1995 Jul 28;270(30):17953-61 - PubMed
  21. J Pharmacol Exp Ther. 2008 Mar;324(3):1196-203 - PubMed
  22. N Engl J Med. 1984 Sep 27;311(13):819-23 - PubMed
  23. Circulation. 2009 Jan 6;119(1):89-98 - PubMed
  24. Br J Pharmacol. 2012 Aug;166(8):2430-40 - PubMed
  25. Lancet. 1992 Jul 11;340(8811):88-92 - PubMed
  26. J Clin Invest. 2007 Sep;117(9):2445-58 - PubMed
  27. Circ Heart Fail. 2012 May 1;5(3):385-91 - PubMed
  28. Am J Physiol Heart Circ Physiol. 2002 Jun;282(6):H1970-7 - PubMed
  29. J Am Coll Cardiol. 1992 Jul;20(1):248-54 - PubMed
  30. Am J Physiol Heart Circ Physiol. 2009 Apr;296(4):H1193-9 - PubMed
  31. Trends Biochem Sci. 2011 Sep;36(9):457-69 - PubMed
  32. J Mol Cell Cardiol. 2002 May;34(5):509-18 - PubMed
  33. Basic Res Cardiol. 2011 Jun;106(4):577-89 - PubMed
  34. J Mol Cell Cardiol. 2011 May;50(5):785-92 - PubMed
  35. Biochem Biophys Res Commun. 2008 Oct 24;375(3):425-9 - PubMed
  36. Acta Cardiol. 1975;30(4):231-7 - PubMed
  37. Am J Physiol Heart Circ Physiol. 2007 Nov;293(5):H3150-8 - PubMed
  38. Circulation. 1991 Sep;84(3):1024-39 - PubMed
  39. J Biol Chem. 2008 May 2;283(18):11954-63 - PubMed
  40. J Mol Cell Cardiol. 2001 Sep;33(9):1589-606 - PubMed
  41. Cell Signal. 2011 May;23(5):794-811 - PubMed
  42. Drug News Perspect. 2004 Jul-Aug;17(6):365-82 - PubMed

Substances

MeSH terms

Publication Types

Grant support